Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19 : A Multicenter Latent Class Analysis
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Although immediate potentially allergic reactions have been reported after dose 1 of mRNA coronavirus disease 2019 (COVID-19) vaccines, comprehensively defined subtypes have not been clearly distinguished.
OBJECTIVE: To define distinct clinical phenotypes of immediate reactions after dose 1 of mRNA COVID-19 vaccination, and to assess the relation of clinical phenotype to mRNA COVID-19 vaccine second dose tolerance.
METHODS: This retrospective study included patients with 1 or more potentially allergic symptoms or signs within 4 hours of receiving dose 1 of an mRNA COVID-19 vaccine and assessed by allergy/immunology specialists from 5 U.S. academic medical centers (January-June 2021). We used latent class analysis-an unbiased, machine-learning modeling method-to define novel clinical phenotypes. We assessed demographic, clinical, and reaction characteristics associated with phenotype membership. Using log-binomial regression, we assessed the relation between phenotype membership and second dose tolerance, defined as either no symptoms or mild, self-limited symptoms resolving with antihistamines alone. A sensitivity analysis considered second dose tolerance as objective signs only.
RESULTS: We identified 265 patients with dose-1 immediate reactions with 3 phenotype clusters: (1) Limited or Predominantly Cutaneous, (2) Sensory, and (3) Systemic. A total of 223 patients (84%) received a second dose and 200 (90%) tolerated their second dose. Sensory cluster (all patients had the symptom of numbness or tingling) was associated with a higher likelihood of second dose intolerance, but this finding did not persist when accounting for objective signs.
CONCLUSIONS: Three novel clinical phenotypes of immediate-onset reactions after dose 1 of mRNA COVID-19 vaccines were identified using latent class analysis: (1) Limited or Predominantly Cutaneous, (2) Sensory, and (3) Systemic. Whereas these clinical phenotypes may indicate differential mechanistic etiologies or associations with subsequent dose tolerance, most individuals proceeding to their second dose tolerated it.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 11(2023), 2 vom: 13. Feb., Seite 458-465.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stone, Cosby A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.02.2023 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2022.08.048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346256798 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346256798 | ||
| 003 | DE-627 | ||
| 005 | 20240314234327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2022.08.048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM346256798 | ||
| 035 | |a (NLM)36108922 | ||
| 035 | |a (PII)S2213-2198(22)00934-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stone, Cosby A |c Jr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19 |b A Multicenter Latent Class Analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.02.2023 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Although immediate potentially allergic reactions have been reported after dose 1 of mRNA coronavirus disease 2019 (COVID-19) vaccines, comprehensively defined subtypes have not been clearly distinguished | ||
| 520 | |a OBJECTIVE: To define distinct clinical phenotypes of immediate reactions after dose 1 of mRNA COVID-19 vaccination, and to assess the relation of clinical phenotype to mRNA COVID-19 vaccine second dose tolerance | ||
| 520 | |a METHODS: This retrospective study included patients with 1 or more potentially allergic symptoms or signs within 4 hours of receiving dose 1 of an mRNA COVID-19 vaccine and assessed by allergy/immunology specialists from 5 U.S. academic medical centers (January-June 2021). We used latent class analysis-an unbiased, machine-learning modeling method-to define novel clinical phenotypes. We assessed demographic, clinical, and reaction characteristics associated with phenotype membership. Using log-binomial regression, we assessed the relation between phenotype membership and second dose tolerance, defined as either no symptoms or mild, self-limited symptoms resolving with antihistamines alone. A sensitivity analysis considered second dose tolerance as objective signs only | ||
| 520 | |a RESULTS: We identified 265 patients with dose-1 immediate reactions with 3 phenotype clusters: (1) Limited or Predominantly Cutaneous, (2) Sensory, and (3) Systemic. A total of 223 patients (84%) received a second dose and 200 (90%) tolerated their second dose. Sensory cluster (all patients had the symptom of numbness or tingling) was associated with a higher likelihood of second dose intolerance, but this finding did not persist when accounting for objective signs | ||
| 520 | |a CONCLUSIONS: Three novel clinical phenotypes of immediate-onset reactions after dose 1 of mRNA COVID-19 vaccines were identified using latent class analysis: (1) Limited or Predominantly Cutaneous, (2) Sensory, and (3) Systemic. Whereas these clinical phenotypes may indicate differential mechanistic etiologies or associations with subsequent dose tolerance, most individuals proceeding to their second dose tolerated it | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adverse reaction | |
| 650 | 4 | |a Allergy | |
| 650 | 4 | |a Anaphylaxis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cluster | |
| 650 | 4 | |a Hypersensitivity | |
| 650 | 4 | |a Phenotype | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a mRNA | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Robinson, Lacey B |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Krantz, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Kwah, Jason H |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Gilbert |e verfasserin |4 aut | |
| 700 | 1 | |a Mancini, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfson, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Saff, Rebecca R |e verfasserin |4 aut | |
| 700 | 1 | |a Samarakoon, Upeka |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Koo, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Timothy G |e verfasserin |4 aut | |
| 700 | 1 | |a Gruchalla, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Jane X |e verfasserin |4 aut | |
| 700 | 1 | |a Kuster, John K |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Ahola, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Banerji, Aleena |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenthal, Kimberly G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 11(2023), 2 vom: 13. Feb., Seite 458-465.e1 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:2 |g day:13 |g month:02 |g pages:458-465.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2022.08.048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 2 |b 13 |c 02 |h 458-465.e1 | ||